For laboratory research use only - not for human consumption

Compound hub · Retatrutide

Retatrutide Phase 2 trial: what did the paper find?

The retatrutide Phase 2 trial was a mid-stage study of 338 adults followed for 48 weeks. Every retatrutide group had a greater body-weight change than the placebo group, which got no active material (Jastreboff et al., NEJM, 2023). The main result, at week 24, was a model-adjusted average of -17.5% in the highest group, against -1.6% for placebo. The model-adjusted average corrects for missed measurements (Jastreboff et al., NEJM, 2023).

Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.

Published 2026-08-21Updated 2026-10-17Written by Form Laboratories research team9 min read

Your body weight never sits perfectly still. It shifts with water, weather, sleep and the shape of an ordinary day. You can see that wobble on a scale even when nothing real has changed. A clinical trial has to turn that moving signal into something it can compare fairly across many people.

That is why a percentage needs its paperwork attached. The paper, the people, the planned end point and the time of measurement all shape what the number can mean. This page is part of the retatrutide hub. It walks through one obesity trial in that order. It starts with the question the trial was built to answer. Then it reads the larger later figure without letting it outrun the study that produced it.

  • Guidethe retatrutide hubRetatrutide research hub: what the compound is, which receptor systems the literature maps it to, what the published trials measured, and how it compares with approved medicines.

Key facts

Key facts for Retatrutide Phase 2 trial: what did the paper find?
Common nameretatrutide
Research codeLY3437943
DeveloperEli Lilly
PaperJastreboff et al., NEJM, 2023;389(6):514-526
RegistryNCT04881760
Trial phasePhase 2
DesignDouble-blind, randomised, placebo-controlled
Participants338 adults, ages 18-75 (51.8% men)
PopulationBMI ≥30 and ≤50, or ≥27 and <30 with a weight-related condition
DiabetesType 1 and type 2 excluded
Treatment period48 weeks, once weekly
Trial armsPlacebo plus four ascending trial-arm levels
Primary end pointBody-weight change at week 24
Key secondary end pointBody-weight change at week 48
Primary result, highest trial arm-17.5% vs -1.6% placebo (week 24, LS mean)
Secondary result, highest trial arm-24.2% vs -2.1% placebo (week 48, LS mean)
Trial dates20 May 2021 - 22 Nov 2022
Sites28 (United States and Puerto Rico)
FunderEli Lilly and Company
Results first posted13 September 2023
Trial phase as of 2026Phase 3
NEJM 2023

What did the retatrutide Phase 2 trial find?

The Phase 2 retatrutide trial found greater model-adjusted body-weight change in every trial group than with placebo (Jastreboff et al., New England Journal of Medicine, 2023). It was a double-blind, randomised, placebo-controlled study. It followed 338 adults for 48 weeks on a once-weekly schedule. The primary end point was the least-squares mean percentage change in body weight at week 24. It was -17.5% in the highest trial arm against -1.6% with placebo. A least-squares mean is a model average that adjusts for people who missed measurements. The week-48 figures in the same paper were secondary results.

The order matters. The paper asked its main question at the earlier time point. It treated the later reading as supporting evidence. Starting with the biggest number would tell the story backwards.

A placebo-controlled study gives the trial a reference group. That group follows the same study plan without the active trial drug. The reference group is the whole point. Without it, nobody can tell how much of a change comes from the compound. Some of it may come from being watched, weighed and asked about your week for a year.

  • GuideretatrutideA plain-English guide to LY3437943: what it is, the three receptor systems, what each trial phase found, and where the evidence stops.
NEJM 2023ClinicalTrials.gov NCT04881760

Evidence limits

What has this Phase 2 paper not shown?

This Phase 2 paper has not shown a Phase 3 result, a comparison with an approved medicine, or a blood-sugar outcome (Jastreboff et al., NEJM, 2023; ClinicalTrials.gov NCT04881760). The trial compared retatrutide with placebo. It did not compare it with semaglutide, tirzepatide or another medicine. So it was not a head-to-head study. People with type 1 or type 2 diabetes were excluded. So this trial says nothing about blood-sugar outcomes. The paper can answer a narrow obesity-trial question under its own entry rules. It cannot answer how retatrutide compares with another treatment. It cannot say how the compound behaved in people with diabetes.

The difference is easy to lose in a headline. This paper is Phase 2. How long retatrutide has been studied follows the later Phase 3 record. The trial also ran against placebo. So how retatrutide, Mounjaro, and Ozempic differ is the better place for a careful comparison of separate records.

It is worth saying plainly where this page stops. The record we could open is the PubMed abstract and the ClinicalTrials.gov entry. The full NEJM text sits behind a paywall. Confidence intervals, baseline mean weight, dropout rates and the detailed adverse-event tables are not in that record. So they are not here either. Nothing on this page estimates them.

NEJM 2023ClinicalTrials.gov NCT04881760

How was the retatrutide Phase 2 trial designed?

The retatrutide Phase 2 trial assigned 338 adults across seven groups under a double-blind design. That means neither participants nor investigators knew the assignment (Jastreboff et al., NEJM, 2023). Participants were randomised, which means assigned by chance. The ratio was 2:1:1:1:1:2:2 across four ascending trial-arm levels and placebo. Two of those four levels were each reached by two separate groups. That is why seven groups report as five columns. Entry needed a body-mass index of 30 or above, or 27 to under 30 with a weight-related condition. ClinicalTrials.gov NCT04881760 sets the upper limit at 50.

ClinicalTrials.gov NCT04881760 records adults aged 18 to 75 at 28 sites in the United States and Puerto Rico. The trial ran from 20 May 2021 to 22 November 2022. Eli Lilly and Company funded the study (Jastreboff et al., NEJM, 2023).

Why build a trial with two roads to the same level? How a group arrives somewhere can change what happens on the way. The researchers wanted that on the record. The abstract then combines each of those pairs when it reports results. The weekly rhythm of the study is a design choice too. Retatrutide's published pharmacokinetics explains why a weekly gap was worth studying.

  • GuideRetatrutide's published pharmacokineticsRetatrutide's pharmacokinetics as published in two early human studies, what each study enrolled and measured, and what has not been measured. Research material is not a medicine.
NEJM 2023ClinicalTrials.gov NCT04881760

Is the 24.2% figure the trial's main result?

No. The primary end point of the retatrutide Phase 2 trial was the percentage body-weight change at week 24 (Jastreboff et al., NEJM, 2023; ClinicalTrials.gov NCT04881760). The least-squares means at that point were -7.2% in the lowest trial arm, -12.9% and -17.3% in the two combined middle levels, and -17.5% in the highest. Placebo was -1.6%. The week-48 values across those same groups were -8.7%, -17.1%, -22.8% and -24.2%, against -2.1% with placebo. Those later figures were registered as a secondary end point.

A primary end point is the main question a trial is designed and powered to answer. A secondary end point adds context. It does not become the main question just because its number is larger. The -24.2% figure travels furthest online for that very reason.

The paper reports combined results for each pair of groups that reached the same level by different routes. The record we could open does not give a separate result for each of those groups (Jastreboff et al., NEJM, 2023).

Jastreboff et al., NEJM, 2023Jastreboff et al., NEJM, 2026ADA briefing, 6 June 2026

Did the checked retatrutide summaries give a four-week result?

The retatrutide summaries checked here do not give a four-week weight result. The 2023 NEJM summary reports its main reading at 24 weeks. It also reports a later reading at 48 weeks. The 2026 NEJM summary covers 80 weeks. These are separate trials and time points. They do not give a personal forecast for the first month.

An abstract is the short summary at the start of a paper. These checks cover the abstracts, not every chart in the full papers. The lack of a four-week figure here does not mean nobody was weighed then.

Jastreboff and colleagues reported both obesity studies, in NEJM in 2023 and 2026. The June diabetes briefing reports a separate study at 40 weeks. These sources were checked 17 October 2026. Dividing a later result by the months passed assumes a steady change. These summaries do not show that pattern.

Two reported study readings sit above a separate empty monthly forecast card. Labels read Main reading, Later reading, No monthly forecast.
The Phase 2 abstract reports main and later readings. Those readings do not establish a personal monthly forecast. Source: Jastreboff et al., NEJM, 2023, DOI 10.1056/NEJMoa2301972.
NEJM 2023

How many participants reached 5%, 10%, or 15%?

In the retatrutide Phase 2 trial at 48 weeks, some people reached body-weight changes of at least 5%, 10% and 15%. In the second trial-arm level the shares were 92%, 75% and 60%. In the third they were 100%, 91% and 75%. In the highest they were 100%, 93% and 83%. On placebo they were 27%, 9% and 2% (Jastreboff et al., NEJM, 2023). A responder threshold is a fixed bar counted person by person. It is not an average across a whole group. The abstract we could open gives no responder row for the lowest trial arm, so this page does not guess one.

An average and a responder percentage answer different questions. The average says where the group sat as a whole. It can hide both the people who barely moved and the people who moved a great deal. The responder rows count how many people crossed each line. Neither reading is complete alone. That is why the paper prints both.

The placebo column belongs in the answer too. Some participants crossed the first threshold without the active trial drug at all. A reference group exists to show exactly that.

NEJM 2023

What did the Phase 2 trial report about side effects?

The retatrutide Phase 2 trial reported that the most common adverse events were gastrointestinal. They were linked to the trial-arm level and mostly mild to moderate (Jastreboff et al., NEJM, 2023). The paper says those events were partly eased in the groups that began from the lower of the two starting points. It also reports increases in heart rate that tracked the trial-arm level. They peaked at 24 weeks and fell afterwards. Those lines are the full safety detail in the abstract we could open. They do not support a wider heart-health conclusion in either direction.

Tracking the trial-arm level means the pattern changed as the assigned label changed. Researchers watch for that kind of gradient. A signal that scales with the arm is harder to wave away as chance than one that shows up in a single group.

The detailed adverse-event tables and the dropout rates sit behind the journal paywall. We did not retrieve them. This page keeps the paper's own wording and stops where the open record stops.

NEJM 2023

Is research-use retatrutide the same material this trial used?

No. The retatrutide figures on this page came from a trial drug product used under clinical trial conditions. It involved 338 adults under medical supervision (Jastreboff et al., NEJM, 2023). Research-use reference material is a laboratory compound, not that trial product. The difference matters because a result belongs to the exact material, people and protocol that produced it. Research material is not a medicine, not a substitute for one, and not for human or animal use. Nothing in this paper turns a trial-arm label into an instruction. Nothing in it turns a group result into an outcome any reader should expect.

Laboratory buyers can check availability and lot details for retatrutide reference material. That is a catalogue and paperwork question, not a clinical one. The quality and verification hub explains what a certificate records, what a third-party report can show, and how a batch stays tied to its own documents.

Comparison

Least-squares mean percentage change in body weight, retatrutide Phase 2 obesity trial (NCT04881760, n=338). Week 24 is the primary end point. Week 48 is secondary. The second and third rows each combine two groups that reached the same level from different starting points. These are trial-arm labels, not use directions.

Comparison: Retatrutide Phase 2 trial: what did the paper find?
Trial groupWeek 24 (primary)Week 48 (secondary)
Placebo-1.6%-2.1%
Lowest trial arm-7.2%-8.7%
Second trial arm (combined)-12.9%-17.1%
Third trial arm (combined)-17.3%-22.8%
Highest trial arm-17.5%-24.2%

FAQ

What did the retatrutide Phase 2 trial show?

In 338 adults followed for 48 weeks, the highest trial arm had a secondary least-squares mean body-weight change of -24.2%. Placebo was -2.1%. The primary week-24 values were -17.5% and -1.6% (Jastreboff et al., NEJM, 2023).

Is 24.2% the main result of the retatrutide Phase 2 trial?

No. The -24.2% value was a secondary end point at week 48 in the highest trial arm. The primary end point was week 24. At that point the group recorded -17.5% against -1.6% with placebo (Jastreboff et al., NEJM, 2023).

How many people were in the retatrutide Phase 2 trial?

ClinicalTrials.gov NCT04881760 lists 338 enrolled adults aged 18 to 75. Its 28 locations were in Puerto Rico and the United States. The study ran between 20 May 2021 and 22 November 2022.

Did the retatrutide Phase 2 trial include people with diabetes?

No. Type 1 and type 2 diabetes were exclusion criteria. So this trial does not report blood-sugar outcomes for people with diabetes (ClinicalTrials.gov NCT04881760).

Citations

2 sources
  1. Jastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
    doi:10.1056/NEJMoa2301972

  2. Jastreboff AM et al. New England Journal of Medicine. 2026; TRIUMPH-1; published 29 September.
    doi:10.1056/NEJMoa2604169

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Continue

Retatrutide reference material

Research use only - not for human or animal use.

Read the retatrutide research guide

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease